Corbus Pharmaceuticals Holdings, Inc. · NASDAQ:CRBP
Corbus Pharmaceuticals — Investor Presentation (April 2022)
29 slides from Corbus Pharmaceuticals's investor presentation, Apr 11, 2022
Slide 1: Connecting Innovation to Purpose
PHARMACEUTICALS Connecting ~. Innovation to Purpose
Slide 2: Forward-Looking Statements
- an Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to t
Slide 3: Corbus Pharmaceuticals
Corbus Pharmaceuticals Immunology company focused on developing novel therapeutics through distinct platforms: Immuno-Oncology (10) Portfolio Hescedeeeteteaseevehdedsnesueeesenseere NASDAQ: CRBP + Anti-Integrins targeting + CB1 Inverse Agonist the TGFB axis * CB2 Agonist + Expanding IO pipeline thro
Slide 4: Solid Tumors
Solid Tumors Anti-avB8 mAb Anti-avB6/avB8 Solid Tumors / Fibrosis mAb Endocannabinoid Portfolio CB2 Agonist CRB-913 - Obesity / Metabolism x ™ CB1 Inverse Agonist
Slide 5: Focus on Immune Resistant Cancers for expansion of the Corbus pipeline
Focus on Immune Resistant Cancers for expansion of the Corbus pipeline Mechanisms of Action in Focus Suppressors of Immune Surveillance Immune suppressive Soluble factors/enzymes Seeking to bring in other assets with the potential to be first or best-in-class Dysregulation of T-cell check points Ine
Slide 6: Internal Development Focus: Immuno-Oncology Portfolio
INTERNAL DEVELOPMENT FOCUS Immuno-Oncology Portfolio Innovative control of the TGFB axis
Slide 7: TGFB has been associated with immune cell exclusion in cancer
+ TGFB has been associated with @ immune cell exclusion in cancer Pro-inflammatory + Targeting TGFB has been challenging Epithelium Tumor stroma (oy) — Local tumor versus systemic signaling may be key Anti-inflammatory TGF-B D103 E-Cadherin Epithelial cells Fibroblasts Tumor cells Inhibition Inducti
Slide 8: TGFB predicts poor clinical outcomes in a subset of cancer patients
TGF predicts poor clinical ou cancer patients Immunogenomic subtypes in cancer [EG wounn teauins INF-y DOMINANT [ sremmatory LYMPHOCYTE DEPLETED [cs | IMMUNOLOGICALLY QUIET TGFB DOMINANT TGFB predominance gene signature e Source: Thorsson, et al. The Immune Landscape of Cancer, Immunity. 2018; 48:81
Slide 9: Successfully blocking TGFB overcomes immune exclusion
Successfully blocking TGFB overcomes immune exclusion ¥ Isotype control Ab Anti-PD-L1 Ab Anti-TGFB Ab Combination Stromal TGFB signaling is a determinant of immuno-exclusion2 peeks ee Volume (mm) CR=10% CR=0% 0.5 10 15 20 25 30.35 40 «0 5 10 15 2025 3035 40 0 5S 10 15 2025303540 9 ORE; 5 10 15 20 25
Slide 10: Targeting the integrin avB8 represents a novel approach to regulating TGFB
Targeting the integrin avB8 represents a novel approach to regulating TGFB Recent experience with TGFB' TGFB pathway Compoun Modality Anti sense TGFB2 Trabedersen Anti sense oligo avB3/5 Integrin Sian inhibitor Cilengitide avB3/5 mAb TGFBRI blockade LY3022859 mAb TGF ligand Trap Fresolimumab mAb TGF
Slide 11: Remaining unmet need in IO therapies is driving innovation
Remaining unmet need in IO therapies is driving innovation New Approaches to Targeting TGFB? Phase (Disclosed indication) Target eo eee se 1 . . . . : IND H1-2023 ee ed 2 CORBUS Solid Tumors cues VY ATR Phase 1 Pfizer Solid firmer oups VY vy of metastatic cancer patients do not BS Scholar Phase 1 CA
Slide 12: CRB-601 demonstrates low nano-molar binding and high selectivity to avB8
CRB-601 demonstrates low nano-molar binding and high selectivity to avB8 L-TGFB Protein Binding Assay? TGFR binding to avB8' The ability of CRB-601 to block the CRB-601 1C50 = 3.7 nM binding of L-TGFB to avB8 was measured in a cell-based % Adhesion 8 competition assay. 50 pro- L-TGF-6 . domain 0.1 4
Slide 13: CRB-601 single agent activity and combination benefit with anti-PD1
CRB-601 has single agent activity and demonstrates combination benefit with anti-PD1 in an immune non-responsive model Wood i 4 cRB-601, 30 mg/kg, IP Days o 3 Fl 4} Anti-PD-1 (RMP1-14), 10 mg/kg, IP 1600 TG! (%) # Isotype control EM T6! 1400 Anti-PD-1 | -8 ~@-Anti-PD-1 An immune non-responsive synge
Slide 14: CRB-601 combination benefit with anti-PD1 in an immune responsive model
CRB-601 continues to demonstrate combination benefit with anti-PD1 in an immune responsive mode! - , cae Treatment Late-stage intervention ae uoto4w ¥ CRB-601,10 marke, IP = 3) (Tumor volume = 200 mm?) Tay DayO Day3 Day? ¥ Anti-PD-1, 10 mg/kg, IP 2200 xk! = Anti-PD-1 54 1800 MC382 a ae % 1600 te sot
Slide 15: Tumor reduction by CRB-601 correlates to CD8+ T cell infiltration
Tumor reduction by CRB-601 correlates to CD8+ T cell infiltration yi and proliferation within TME Tumor weight (g) . oe ape A 6 Proliferation PD-1 expression in gelite eal eLeT of CD8* TILs CD8*TILs 12 lymphocytes (TILs) ee [xe s & o Tumor Weight, g & CD8+ T Cells (x10%/g Tumor) (CD8+Ki67+ T Cells (
Slide 16: CRB-601 + anti-PD1 is associated with tumor-specific immune memory
CRB-601 + anti-PD1 is associated with tumor-specific immune memory Day-8 MC38 SC uuu ses sefeetiton | €RB-601, 1P implantation P| wa Ge eas oy } Anti-PD-1 (RMP1-14), 10 mg/kg, IP Surviving MC38 tumor bearing mice treated with CRB-601 + anti-PD1 were mm 7 re-challenged with MC38 tumors and compared t
Slide 17: Opportunities to differentiate the development of CRB-601
Corbus may have significant opportunities to differentiate the development of CRB-601 Features of Example: Differentiation Strategic differentiation in PD-1 therapy 10 TREATMENT aie Pre Clinical 4 OPDIVO. ; feenchmer LLL Phase 1 design v » Modality ~ Ig Class KEYTRUDA ° a (pembrolizumab)ie:ion 100mg
Slide 18: CRB-602 is a unique asset for fibrotic diseases and fibrotic cancers
CRB-602 is a unique asset and may provide potential therapeutic benefit in fibrotic diseases and fibrotic cancers * CRB-602 is the only monoclonal antibody in development with dual specificity for both avB6 and avB8 Fibrosis, aed + Arational approach to treating inflammation and ao ; fibrotic diseas
Slide 19: Endocannabinoid Portfolio: CRB-913
ee N ENDOCANNABINOID PORTFOLIO CRB-913: 2nd Generation CB1 Inverse Agonist for Metabolic Diseases Exploring Potential Partnership Opportunities ep
Slide 20: Obesity is a global epidemic creating significant societal burden
Obesity is a global epidemic creating significant societal burden with need ° for improvement on top of standard of care (incretin analogues, e.g. GLP-1) Dual-pharmacology holds great promise as a potential treatment option in obesity 41% $2T of worldwide adults annual global medical 0% projectedtob
Slide 21: CB1 Inverse Agonist targeting large metabolic disease market
CB1 Inverse Agonist targeting large metabolic disease market Innovation + Rationally designed to achieve markedly reduced brain exposure to address psychiatric side effects with 1st generation CB1 inverse agonists — Potential to augment effects of GLP-1R agonists in diabetes and obesity — Combinatio
Slide 22: CRB-913: differentiated CB1 inverse agonist inducing weight loss with semaglutide and tirzepatide
CRB-913: a differentiated CB1 inverse agonist inducing ¥ weight loss in combination with semaglutide and tirzepatide Diet Induced Obesity (DIO) Mouse Model CRB-913 demonstrates a markedly reduced brain CRB-913 reduces weight both as single agent exposure vs. Rimonabant and in combination (Day 18) 10
Slide 23: Endocannabinoid Portfolio: Lenabasum
ee N ENDOCANNABINOID PORTFOLIO Lenabasum: A Late-stage CB2 Agonist for Autoimmune Diseases Exploring Potential Partnership Opportunities a
Slide 24: Lenabasum is a late-stage clinical asset that presents significant opportunity
Lenabasum is a late-stage clinical asset that presents significant opportunity OPPORTUNITY + First in class CB2 agonist * Capable of combining with existing SoC due to Non-immunosuppressive profile + Large safety database * Clinical signals indicating potential for trial refinement in DM, SSc, and C
Slide 25: Lenabasum effects on skin in DM present an opportunity for trial enrichment
Lenabasum effects on skin in DM presents an opportunity for future trial enrichment Dermatomyositis (DM) is a heterogenous rare disease Clinical PoC! characterized by a distinctive skin rash and muscle weakness* Lenabasum Phase 2 in amyopathic (skin predominant) DM ES 5 ao) 5 3 = ra 5 50 a 2 A 5 Cla
Slide 26: Management Team
Management Team Yuval Cohen, PhD Chief Executive Officer, Director Corbus co-founder and Chief Executive Officer since 2014. Previously the President and co-founder of Celsus Therapeutics from 2005 Rachael Brake, PhD Chief Scientific Officer Expert in developing and executing innovative drug discove
Slide 27: Board of Directors
Board of Directors Amb. Alan Holmer Ret. Chairman of the Board More than two decades of public service in Washington, D.C. including Special Envoy to China; Former CEO of PhRMA Rachelle Jacques Director More than 25-year professional career, exp ience in U.S. and global biopharmaceutical commercial
Slide 28: Investment Summary
Investment Summary $98.3 Million Cash and investments as of December 31, 2021 125.2M Common Shares Outstanding ee (145.2 M Fully Diluted) wad Engaging in business development activities to expand (ep immuno-oncology pipeline
Slide 29: Corbus Pharmaceuticals
CORBUS PHARMACEUTICALS
Corbus Pharmaceuticals Holdings — Investor Presentation (April 2022) on 6ix